The latest announcement is out from Microbot Medical ( (MBOT) ).
On April 9, 2025, Microbot Medical announced the successful presentation of data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology annual meeting. The trial demonstrated that the LIBERTY® Endovascular Robotic System achieved a 100% success rate in robotic navigation with no adverse events, and significantly reduced radiation exposure by 92%. The results highlight the system’s feasibility and potential market impact, as the company prepares for its commercial launch pending FDA clearance.
More about Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally. The company has developed the world’s first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems.
YTD Price Performance: 21.93%
Average Trading Volume: 2,380,926
Technical Sentiment Signal: Buy
Current Market Cap: $52.46M
For detailed information about MBOT stock, go to TipRanks’ Stock Analysis page.